天坛生物
(600161)
| 流通市值：294.23亿 | | | 总市值：294.23亿 |
| 流通股本：19.77亿 | | | 总股本：19.77亿 |
| 报告期 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,168,036,314.63 | 4,465,071,868.98 | 3,110,392,965.34 | 1,317,766,404.91 |
| 营业收入 | 6,168,036,314.63 | 4,465,071,868.98 | 3,110,392,965.34 | 1,317,766,404.91 |
| 二、营业总成本 | 4,315,509,249.08 | 3,110,810,892.92 | 2,079,476,311.38 | 908,034,937.26 |
| 营业成本 | 3,463,231,712.76 | 2,508,783,669.51 | 1,698,258,337.49 | 713,279,217.18 |
| 税金及附加 | 73,398,596.62 | 50,489,295.1 | 31,863,323 | 13,238,297.74 |
| 销售费用 | 124,903,052.79 | 90,082,081.48 | 60,356,476.12 | 34,343,579.04 |
| 管理费用 | 496,043,575.85 | 358,242,659.95 | 232,973,894.35 | 118,340,412.34 |
| 研发费用 | 159,993,236.22 | 103,154,562.83 | 56,936,180.12 | 30,297,221.48 |
| 财务费用 | -2,060,925.16 | 58,624.05 | -911,899.7 | -1,463,790.52 |
| 其中:利息费用 | 7,336,021.88 | 7,571,310.11 | 4,337,436.62 | 2,403,980.7 |
| 其中:利息收入 | 12,085,262.91 | 9,431,006.69 | 6,510,633.51 | 4,450,202.9 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 26,979,259.67 | 25,892,627.46 | 22,432,891.35 | 8,958,360.98 |
| 资产处置收益 | 104,452.59 | 204,679.09 | 204,679.09 | 204,679.09 |
| 资产减值损失(新) | -19,110,612.28 | -7,482,874.86 | -3,801,539.47 | -1,747,267.39 |
| 信用减值损失(新) | -65,197,479.13 | -51,353,589.07 | -33,550,584.65 | -19,718,691.93 |
| 其他收益 | 42,005,309.19 | 32,761,718.17 | 25,759,579.95 | 8,818,518.86 |
| 四、营业利润 | 1,837,307,995.59 | 1,354,283,536.85 | 1,041,961,680.23 | 406,247,067.26 |
| 加:营业外收入 | 2,763,350.32 | 1,984,135.74 | 1,845,000.68 | 292,883.21 |
| 减:营业外支出 | 17,347,553.51 | 8,870,391.23 | 5,436,525.64 | 261,459.89 |
| 五、利润总额 | 1,822,723,792.4 | 1,347,397,281.36 | 1,038,370,155.27 | 406,278,490.58 |
| 减:所得税费用 | 332,841,612.7 | 226,940,153.37 | 172,570,069.13 | 68,995,470.46 |
| 六、净利润 | 1,489,882,179.7 | 1,120,457,127.99 | 865,800,086.14 | 337,283,020.12 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,489,882,179.7 | 1,120,457,127.99 | 865,800,086.14 | 337,283,020.12 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,090,837,981.2 | 818,686,340.45 | 632,562,146.1 | 244,145,675.45 |
| 少数股东损益 | 399,044,198.5 | 301,770,787.54 | 233,237,940.04 | 93,137,344.67 |
| 扣除非经常损益后的净利润 | 1,076,327,393.28 | 802,892,461.06 | 618,015,305.4 | 239,155,852.86 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.55 | 0.41 | 0.32 | 0.12 |
| (二)稀释每股收益 | 0.55 | 0.41 | 0.32 | 0.12 |
| 九、综合收益总额 | 1,489,882,179.7 | 1,120,457,127.99 | 865,800,086.14 | 337,283,020.12 |
| 归属于母公司股东的综合收益总额 | 1,090,837,981.2 | 818,686,340.45 | 632,562,146.1 | 244,145,675.45 |
| 归属于少数股东的综合收益总额 | 399,044,198.5 | 301,770,787.54 | 233,237,940.04 | 93,137,344.67 |
| 公告日期 | 2026-03-28 | 2025-10-25 | 2025-08-22 | 2025-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |